Over the past few years, osimertinib has received much fanfare among lung cancer experts. Results from the phase 3 LAURA trial were met with a standing ovation at the 2024 American Society of Clinical Oncology annual meeting, after the trial demonstrated a 33.5-month progression-free survival benefit in patients with EGFR-mutated unresectable stage 3 non–small cell lung …
